Trials / Completed
CompletedNCT04724109
A Study of Equfina® on the Incidences of Adverse Drug Reactions in Participants With Parkinson's Disease (Including Participants With Hepatic Impairment)
Protocol for Study EQF01S: General Drug Use-Results Observational Study of Equfina® TABLETS 50 mg Observational Study on the Incidences of Adverse Drug Reactions in Patients With Parkinson's Disease (Including Patients With Hepatic Impairment)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,088 (actual)
- Sponsor
- Eisai Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to investigate the incidences of psychiatric symptoms (example, hallucinations), somnolence and sudden onset of sleep, dyskinesia, and retinal degeneration-related events during treatment with Equfina in participants with parkinson's disease (including participants with hepatic impairment).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Equfina | Equfina oral tablets. |
Timeline
- Start date
- 2020-10-14
- Primary completion
- 2022-10-13
- Completion
- 2022-10-13
- First posted
- 2021-01-26
- Last updated
- 2022-12-16
Locations
2 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT04724109. Inclusion in this directory is not an endorsement.